Analytical Data
-
基因名
U2AF1L3
- Application
-
别名
Splicing factor U2AF 26 kDa subunit. U2 auxiliary factor 26. U2 small nuclear RNA auxiliary factor 1-like Protein 4. U2AF1-like 4. U2(RNU2) small nuclear RNA auxiliary factor 1-like Protein 3. U2 small nuclear RNA auxiliary factor 1-like Protein 3. U2AF1-like Protein 3
-
种属
Human
-
表达系统
E. coli
-
标签
GST-tag at N-terminal
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
Q8WU68
-
表达区间
1-202 aa
-
氨基酸序列
MAEYLASIFGTEKDKVNCSFYFKIGVCRHGDRCSRLHNKPTFSQEVFTELQEKYGEIEEMNVCDNLGDHVVGNVYVKFRREEDGERAVAELSNRWFNGQAVHGNVPEVASATSCICGPFPRTSRGSSMGGDPGAGHPRGSILATIPERGTIGVPLITGMAASEALAPLPFTPNRDRCSWQDLSSKPPSLSCPILPRLPGSIM
-
分子量
48.4 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
U2AF1L3, a member of the U2AF (U2 small nuclear RNA auxiliary factor) protein family, plays a critical role in the regulation of pre-mRNA splicing by binding to the poly-pyrimidine tract of introns in mRNA precursors. Given its involvement in essential cellular processes, including gene expression and regulation, U2AF1L3 has garnered significant interest in the context of various diseases, particularly cancers. Recent studies have identified mutations in the U2AF1 gene, leading to abnormal splicing events that contribute to tumorigenesis. Moreover, the exploration of U2AF1L3 as a potential therapeutic target is gaining momentum, with researchers investigating its structural characteristics and interactions with other splicing factors. The recombinant protein of U2AF1L3 is crucial for elucidating its biochemical properties and understanding its role in the splicing mechanism. By producing U2AF1L3 in a recombinant form, scientists aim to study its activity in vitro, which could lead to insights into how mutations affect its function and how this, in turn, influences disease progression. Therefore, research on U2AF1L3 and its recombinant protein serves as a vital avenue for uncovering the complexities of RNA processing and identifying potential intervention strategies in splicing-related diseases.
